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Abstract
Introduction: The purpose of this article is to determine the prevalence of ONJ in patients 
who have undergone intravenous bisphosphonate therapy, and relate the risk factors 
described (including Actinomices); indeed, to establish a protocol to reduce the risk of 
developing ONJ and to evaluate the evolution of the patient according to the sample’s 
antibiogram.
Results: The prevalence of ONJ was 12.9%. Most of the non-diabetic patients did not 
develop ONJ (92.3%) (p = 0.048). In regards to the periodontal state, 94.3% of patients 
without periodontal problems did not develop ONJ (p = 0.001). Almost 50% of the necro-
sis were unifocal and located on the mandible (p < 0.001). The number of affected patients 
and the aggressiveness of the disease increased significantly three years after starting 
treatment (p < 0.001). 87.5% of biopsies showed the presence of Actinomyces. The inflam-
matory response was very variable, ranging from absent to intense but it increased with 
age (p = 0.005). The combination of amoxicillin with clavulanic acid showed good sensi-
tivity in the majority of patients (82.6%).
Conclusions: As the etiology of ONJ remains unknown, it is essential to prioritize pre-
vention while assessing the risk factors.
Keywords: osteonecrosis, bisphosphonates, prevalence, risk factors, microbiota, inflammation, 
actinomyces
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1. Osteonecrosis of the jaws
1.1. History
The term osteonecrosis dates back to the 1950s, when a series of cancer patients who underwent 
radiotherapy developed bone lesions on the jaws following the treatment [1–3]. This treatment, 
which is currently resulting in many complications on an oral level, makes it very hard to cure 
infections that are sometimes inevitable for these patients, since ischemia takes place on the 
jaws.
Some years later, the first article appeared citing a periapical lesion following arsenic infiltra-
tion for canal treatment. Arsenic was used as a therapeutic agent and as poison in Ancient 
Greek and Roman times [4]. It was also used as an agent during dental history for pulp devi-
talization, when anesthetics did not exist. Due to its ability to destroy cells in surrounding 
tissues, the use of arsenic trioxide in vital pulpectomy has been dropped progressively [5]. 
Dumlu’s article (2007) described a case of jaw necrosis in a young patient following tooth 
extraction of a first failed molar after arsenic treatment of the canals [6]. Toxavit, another devi-
talizing agent, has also been related to bone necrosis. In any case, both agents are currently 
obsolete for these dental treatments [7, 8].
Another one of the causes mentioned in the history of osteonecrosis is the untreated intra-
capsular fracture, after several months, the described clinical symptoms were pain in the 
temporal-jaw articulation in the affected side and the limitation in opening the jaw. On a 
radiographic level, the condylar head is usually eroded and irregular [9].
Back in 1982, the first cases of osteonecrosis of the jaw in toothless patients by chemotherapy 
treatment were published. Specifically, the article considered the origin was a lesion on the 
mucosa due to a trauma caused by removable prosthesis.
The cases of aseptic osteonecrosis after jaw osteotomy following orthognathic surgeries have 
also been described in the literature; they have been related mostly to a complication follow-
ing a surgical error [10].
In 2002, a clinical case of osteonecrosis of the jaws due to chemotherapy in a patient with 
myelogenous leukemia was published [11]; and, a year later, the current term bisphospho-
nates-related osteonecrosis of the jaws was branded (BRONJ) [12].
Despite the osteonecrosis of the jaws was exclusively related to the mouth, some rare cases in 
the external ear, the hip, the tibia and the femur have been documented [13, 14].
1.2. Definition
The concept of osteonecrosis of the jaws was introduced in 2003 when a series of 36 bone 
lesions in the mandible and the maxilla were described in patients undergoing treatment with 
pamidronate or zoledronate [12].
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Then in 2007, the American Association of Oral and Maxillofacial Surgeons (AAOMS) 
described osteonecrosis of the jaws like persistent bone exposure in the mouth for over 8 
weeks in patients with a history of use of bisphosphonates, without local evidence of malig-
nancy or radiotherapeutic treatment of the affected region [15].
Despite that the term osteonecrosis has been used in numerous contexts and even in dif-
ferent locations (not only for the jaws); it is currently related exclusively to the chronic use 
of bisphosphonates. The condition is called bisphosphonate-related osteonecrosis of the jaw 
(BRONJ) [16], which was changed by the AAOMS in 2014 for the term medication-related 
osteonecrosis of the jaw (MRONJ), since this complication has also been described in relation 
to other antiresorptive drugs (denosumab) and antiagiogenic therapies [17].
1.2.1. Prevalence and incidence
The prevalence of osteonecrosis of the jaws is variable according to the consulted authors, 
reaching approximately 7–12%, although in more recent articles it tends to be even higher 
(18.6%) [18].
In regards to IV bisphosphonates, the bibliography of a series of cases, case studies and con-
trols and cohorts, the estimations of the accumulated incidence of MRONJ ranges from 0.8 to 
12% [19].
In regards to oral bisphosphonates, clinical effectiveness has been proven, which is shown in 
over 190 million prescriptions of these drugs around the globe [20]. Despite that osteonecrosis 
cases have been described, these patients have a considerably lower risk of MRONJ than can-
cer patients who have been treated with monthly IV bisphosphonates.
According to the database of the alendronate manufacturer (Merk), the incidence of MRONJ 
was calculated as 0.7/100.000 people/years of exposure [21]. This derives from the number of 
(non-confirmed) reports of the cases that were considered as MRONJ, divided between the 
number of alendronate pills prescribed since the approval of the drug. Although this is the 
best information available to date, there could be a bias in the collection and validity of the 
data.
In Australia, MRONJ incidence in patients receiving weekly alendronate treatment ranges 
between 0.01 and 0.04% [22]
Felsenberg registered a prevalence of MRONJ among patients who underwent bisphospho-
nates therapy for osteoporosis of 0.00038%, based on the reports of three cases in the German 
Central Register for Jaw Necrosis [23].
1.3. Risk factors
1.3.1. Local factors
A. Dentoalveolar surgery
• Extractions
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• Dental implants
• Periapical surgery
• Periodontal surgery
Cancer patients treated with IV bisphosphonates and who underwent dentoalveolar proce-
dures had 5–21 times more risk of MRONJ than cancer patients who were treated with IV 
bisphosphonates and who did not undergo dentoalveolar procedures [19].
B. Local anatomy
B1. Mandibular
• Lingual torus
• Mylohyoid line
B2. Maxilla
• Palatine Torus
The lesions are located with a higher frequency on the mandible than on the superior maxilla 
(2:1) and more frequently in areas with thin mucosa that cover bone protrusions, such as the 
torus, bone exostosis and the mylohyoid edge [24–26].
C. Concomitant oral diseases: Dental or periodontal abscesses [27].
1.3.2. Systemic and demographic factors
a. Age: Advanced age is related to a higher prevalence of MRONJ.
b. Sex: This factor has not been statistically related to a higher risk of osteonecrosis.
c. Race: Caucasians have a higher risk of MRONJ compared to the Negro race [28].
d. Cancer diagnosis, with or without osteoporosis: The type of malignancy is not statistically 
related to a higher risk of MRONJ, although the presence of bone metastasis presents a 
correlation, according to Wessel’s article (P = 0.051) [29]. It is related with a higher risk of 
osteonecrosis in the coadjuvant treatments in these patients, such as chemotherapeutic 
agents (cyclophosphamide), erythropoietin and steroids [30, 31].
e. Tobacco and alcohol: There is a possible correlation with smoking but not with drinking, 
according to the study published by Wessel et al. [29].
f. Genetic factors: It has been proven that polymorphism in the farnesyl pyrophosphate 
synthase or the cytochrome of gen P450 CYP2C8 increase the risk of MRONJ in patients 
treated with IV bisphosphonates [32–34].
g. Others: Dialysis, low hemoglobin, obesity and diabetes are variables related to MRONJ 
[29, 31, 35].
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1.3.3. Drug-related factors
a. Bisphosphonate potency: IV bisphosphonates present higher power than oral ones [19].
b. Duration of the treatment: The longer the duration of the treatment, higher the risk of 
MRONJ [19].
1.4. Diagnosis
Patients diagnosed with MRONJ are defined by the following characteristics [17]:
1. Prior treatment with antiresorptive and antiangiogenic drugs.
2. Presence of bone exposure or intra- or extraoral fistula for over 8 weeks, without remission.
3. Patients who have not been treated with radiotherapy nor have metastasizing diseases in 
the jaws.
With the intention of standardizing all the signs and symptoms present in the patients 
affected by osteonecrosis of the jaws, a protocol for MRONJ diagnosis was proposed in 2010 
[36].
1.4.1. Clinical diagnosis
a. Greater clinical signs [37]
• Exposed necrotic bone in the oral cavity
b. Minor clinical signs and symptoms
• Abscess
• Displacement of jaw fragments
• Intra-extra oral fistula
• Jaw deformation
• Lip hypaesthesia/paraesthesia
• Gum or mucous fistula
• Nasal level excretions
• Unhealed post-extraction alveoli
• Pus excretion
• Spontaneous expulsion of bone sequestration
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• Dental mobility
• Local inflammation
• Bone and dental pain
• Trismus
1.4.2. Radiographic/tomographic diagnosis
a. Initial signs [38]
• Cortical fracture
• Sclerosis of the focal bone marrow
• Presence of post-extraction alveoli
• Trabecular engrossment
b. Late signs
• Diffuse sclerosis
• Oro-antral fistula
• Osteolysis extended to the sinus floor
• Osteosclerosis of adjacent bones (zygoma and hard palate)
• Pathological fracture
• Prominence of the lower dental nerve canal
• Sinusitis
1.4.3. Diagnosis through complementary testing
The histopathologic study and microbiological culture are also tests developed on the sup-
puration area. Developing an antibiogram is very helpful since these patients will be treated 
with antibiotics during long periods of time and it is convenient to know the existing bacterial 
spectrum and the sensitivity of these microorganisms to different antibiotics.
1.5. MRONJ staging
The stages initially described by Ruggiero et al. [24] have been modified and adapted to clas-
sify patients with greater precision [17, 19, 39] (Figure 1).
Risk patient: Without apparent necrotic lesions in asymptomatic patients undergoing treat-
ments with oral or IV bisphosphonates.
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Stage 0: Patients without clinical evidence of bone necrosis, but with unspecific systems or 
clinical or radiographic findings.
a. Symptoms
• Odontalgia without odontogenic cause.
• Pain at the jaw level that may irradiate to the temporomandibular joint.
• Sinus pain, which may be related to inflammation or engrossment of the maxillary sinus 
wall.
• Alteration of the neurosensory function
b. Clinical findings
• Dental loss without periodontal cause
• Periapical or periodontal fistula that is not related to a pulpal necrosis by cavities.
c. Radiographic findings
• Bone resorption that is not attributable to chronic periodontal disease.
• Changes to the trabeculate and bone density and resistance to healing of the post-extrac-
tion alveoli.
• Widening/darkening of the periodontal ligament.
• Narrowing of the lower dental nerve canal.
These unspecific findings that are characteristic of State 0 can take place in patients with a 
prior history of more advanced phases in whom the disease has been cured and have no clini-
cal evidence of exposed bone.
Stage 1: Asymptomatic bone exposure without clinical signs of inflammation or infection.
Stage 2: Bone exposure with infection and pain, erythema or inflammation of the mucosa, 
with our without suppuration.
Stage 3: Bone exposure associated to pain, inflammation and infection with one or more of 
the following complications:
• Exposed necrotic bone beyond the alveolar region, as the lower border of the mandibular 
branch, maxillary sinus or zygoma.
• Pathological fracture.
• Oro-antral and oro-nasal communication.
• Extra-oral fistula.
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1.6. Treatment
To focus on the treatment to be developed regarding this complication, it is essential to know 
the pathophysiology of MRONJ, only by this way we can draft an appropriate treatment 
plan.
To date, the source has not been adequately documented, describing a multi factor source. 
Suppression of bone remodeling can contribute to the development of osteonecrosis by an 
inadequate activity of osteoclasts that do not allow the post-extraction alveoli to heal. The 
presence of microflora in the mouth have also been related as an osteonecrosis-promoting 
factor, since numerous biopsy studies and bone sequestrations revealed the presence of 
Fusobacterium, Eikenella, Bacillus, Actinomyces, Staphylococcus and Streptococcus [40]. Bacterial 
infection produces local cytokines that promote local osteolysis that contribute to the stimula-
tion of bone resorption and, therefore, subsequent necrosis [41–43].
Additionally, recent articles relate the presence of Actinomyces in MRONJ, although these are 
small studies on a series of cases having a very small impact in establishing a specific treat-
ment strategy [28, 44–46].
Antinomyces are Gram-positive anaerobic facultative bacteria that do not form spores and 
are commonly filamentous. They are frequent commensals of the mucosa in the oropharynx, 
Figure 1. TNM Staging. (A) Stage 1; (B) Stage 2; (C) and (D) Stage 3.
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intestinal tract and the female genital tract, once the mucosa barrier is broken due to trauma, 
surgical interventions or foreign objects, they can invade deep tissue structures and com-
promise treatment response. Progressive chronic disease is called actinomycosis, and the 
treatment of this pathology is based on a prolonged antimicrobial therapy for 2–6 months in 
combination with surgery [47, 48].
1.6.1. Conservative treatment
a. Oral hygiene: Teach the patient good brushing techniques and a good daily control of 
dental plaque.
b. Periodical dental exam: Periodical visits to control the new pathology that could receive 
conservative treatment.
c. Antimicrobial rinses: The mouthwash par excellence is chlorhexidine at 0.12%.
d. Antibiotic treatment: Multiple antibiotic standards have been described, but it is obvious 
that there is an increasing bacterial resistance to penicillins. Running an antibiogram is al-
ways advisable to assess the sensitivity and drug resistance to provide the most appropriate 
treatment.
• Amoxicillin with or without clavulanic acid (500 mg/l g)
• Clindamycin (300 mg)
• Azithromycin (500 mg)
• Metronidazole with betalactamic antibiotics
e. Ozone therapy: Ozone is a natural gas produced by the atmosphere that has antimicrobial 
and healing properties. Its role as a treatment for the osteonecrosis of the jaws has been 
discussed in clinical and pre-clinical studies, since it was believe that this gas induced tis-
sue repair and, therefore, healing of the mucosa [49].
Numerous studies have used this therapy as an adjuvant in antibiotic treatments with good 
results, although further standardized studies are needed to accurately determine their effec-
tiveness [50].
f. Hyperbaric oxygen therapy: Hyperbaric oxygen therapy (HBOT) is very controversial in 
the literature. It is believed that it stimulates tissue healing, reducing edema and inflam-
mation, stimulates cell proliferation and moderates the suppression of bone remodeling 
produced by the use of bisphosphonates [51–53].
g. Soft LASER: This innovative and effective medical method has a pain-reducing effect, 
improving circulation in the lesion and helping nerve regeneration. At an oral level, it im-
proves re-epithelialization following periodontal or third molar surgery [52, 54].
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Most conservative treatments on their own do not show accurate results on their effective-
ness, especially in more advance stages. Authors use them in combination with antibiotics 
and observe that these can help heal the patient, especially in terms of tissue regeneration; but 
it is always reinforced with an appropriate antibiotic treatment (Table 1) [55].
1.6.2. Surgical treatment
For patients in advanced stages and resistant-clinical-cases:
a. Conservative surgery: Includes the remotion of the necrotic bone (sequestration) and/or 
superficial unbinding associated to antibiotic therapy and chlorhexidine rinses.
b. Resective surgery: Destined to patients in whom previous treatments have not been 
effective or have very advanced stages. This process has been questioned since it is 
difficult to guarantee complete resection of the necrosed bone sectioned at the healthy 
bone [56, 57].
Numerous studies show high improvement rates in patients who underwent surgical treat-
ment both in conservative and resective procedures (Table 2) [55].
1.6.3. Other treatments
The use of stem cells [58, 59], platelet-rich plasma [60], the administration of parathyroid hor-
mone [61] or the use of leukocyte- and platelet-rich fibrin [62] are also promising proposals, 
but they require further clinical studies that attest to their effectiveness.
1.6.4. Protocol for the treatment of MRONJ
Risk Patients: They do not require treatment, but must be informed of the risks of developing 
MRONJ, as well as the signs and symptoms of this disease [19, 24].
Type of treatment Author/Year No. patients healed/No. 
patients treated (%)
Antibiotic treatment Melea et al. (2014) 23/38 (60%)
Van den Wyngaert et al. (2009) 16/33 (53%)
Scoletta et al. (2010) 18/30 (62%)
Nicolatou-Galitis et al. (2011) 7/47 (14.9%)
T Antibiotic treatment + hyperbaric oxygen Freiberger et al. (2012) 13/25 (52%)
Antibiotic treatment + ozone therapy Ripamonti et al. (2011) 10/10 (100%)
Pentoxifylline + α-tocopherol Magremanne et al. (2014) 1/1 (100%)
Table 1. Summary of studies with a conservative focus for the management of ONJ-related osteonecrosis [55].
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Stage 0: Symptomatic treatment and control of local factors, such as cavities and periodontal 
disease.
Stage 1: Daily rinses with antimicrobial agents (chlorhexidine at 0.12%) and regular control 
visits.
Stage 2: Oral antimicrobial rinses (chlorhexidine at 0.12%) in combination with antibiotic 
therapy.
Stage 3: Combination of different protocols:
• Surgical debridement of the necrotic bone
• Antibiotic therapy (oral or IV)
• Analgesics
• Daily rinses with antimicrobial agents (chlorhexidine at 0.12%)
Type of treatment Author/Year No. patients healed/No. 
patients treated (%)
Conservative surgery Rugani et al. 2014 15/17 (88.2%)
Vescovi et al. (2012) 11/17 (65%)
Thumbigere-Math et al. (2009) 3/19 (15%)
Williamson et al. (2010) 40/40 (100%)
Vescovi et al. (2014) 25/27 (92.6%)
Graziani et al. (2012) 227 (54%)
Wutzl et al. (2008) 24/41 (519%)
Conservative surgery + ozone therapy Agrillo et al. 57/94 (60%)
Conservative surgery + L-PRF Kim et al. 26/34 (77%)
Resect1ve surgery Graziani et al. (2012) 87/120 (72.5%)
Carlson and Basile (2009) 87/95 (92%)
Bedogni et al. (2011) 27/30 (90%)
Voss et al. (2012) 20/21 (95%)
Schubert et al. (2012) 47/54 (87%)
Note: L-PRF (leukocyte- and platelet-rich fibrin).
Table 2. Summary of studies with a surgical focus for the treatment of MRONJ.
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Regardless of the state of the patient, mobile bone sequestration segments must be retrieved. 
Extraction of affected teeth with symptoms within the exposed necrotic bone must be consid-
ered, since it is improbable that the extraction exacerbates the established necrotic process.
1.7. Prevention
Despite all the treatments proposed above, the latest articles agree that none of these are 
completely effective for all cases, therefore, the main goal in these patients is prevention of 
this complication.
Back in 2009, AAOMS [16] determined that prevention was the main goal in the manage-
ment of these patients, recommending that patients are evaluated and treated before initiating 
bisphosphonate therapy.
There are several studies that document that preventative dental treatment decreases the 
risk of MRONJ among patients with malignant tumors treated with IV bisphosphonates 
[63, 64]. These findings suggest that, although MRONJ is not eliminated, evaluations and 
dental treatment prior to beginning bisphosphonate therapy in cancer patients reduces the 
risk of MRONJ.
Furthermore, they advise revising the doses prescribed to the patients, since it has been 
proven that [65] the accumulative doses can increase the risk of suffering complications.
The risk of developing MRONJ due to oral bisphosphonate treatment is minimal, but it 
seems to increase when the duration of the treatment is more than 3 years. This period of 
time can be reduced in the presence of certain concomitant diseases, such as the chronic 
use of corticosteroids. Systemic conditions permitting the clinician should consider inter-
rupting oral bisphosphonate treatments for a 3-month period before and another 3 months 
after elective invasive dental surgery with the purpose of reducing the risk of MRONJ. The 
justification of this focus is based on extrapolated data that show fluctuations depending on 
osteoclasts, which is related to the treatment with bisphosphonates, and recent studies show 
that there is a better result in the treatment of MRONJ after eliminating the drug [66]. In 
the long term, prospective studies will be necessary to establish the efficacy of suppression 
period of these drugs to reduce the risk of MRONJ in patients undergoing oral bisphospho-
nate treatments.
1.7.1. Patients about to begin bisphosphonate treatment
The goal is to reduce the risk of developing MRONJ to the minimum despite that a small per-
centage of patients who receive IV bisphosphonate therapy can develop osteonecrosis spon-
taneously [19]. Thus, if the medical conditions of the patient allow, the start of the treatment 
must be delayed until their dental health is optimal [63, 64]. This decision must be made by 
the doctor, together with the dentist and other specialists involved in the patient’s care.
Untreatable teeth and those with bad prognosis must be extracted. Additionally, other neces-
sary dentoalveolar surgeries should also be performed at this time. The start of the treatment 
with bisphosphonates, if possible, should be delayed until complete healing of the mucosa 
(14–21 days) or until there is an appropriate bone healing.
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Dental prophylaxis, cavity control and restorative-conservative odontology are essential to 
maintain dental health. This level of attention should be maintained indefinitely. The patients 
with complete or partial prosthesis should be examined to avoid the trauma areas of the 
mucosa, especially in the border of the tongue. It is essential that patients are trained in 
regards to the importance of oral hygiene and regular dental evaluations, and instructed spe-
cifically to report any pain, swelling or exposed bone area.
1.7.2. Asymptomatic patients who receive IV bisphosphonates
Procedures that imply direct bone lesion should be avoided, therefore, unrestorable teeth 
should be treated by eliminating the crown and the endodontic treatment of root fragments 
[21]. The placement of dental implants must be avoided in cancer patients exposed to higher 
potency bisphosphonates (zoledronic acid and pamidronate) with a frequent dose program 
(4–12 times/year).
1.7.3. Asymptomatic patients who receive oral bisphosphonate treatments
In general terms, these patients seem to have less severe manifestations of necrosis and 
respond promptly to the described treatments [67, 68]. Elective alveolodental surgery does 
not seem to be contraindicated in this group, although it is advisable that the patients are 
appropriately informed on the small risk of complications in bone healing. The use of levels 
in the bone exchange markers and a drug break in the treatment have been documented 
as additional tools that guide in making treatment decisions in patients exposed to oral 
bisphosphonates [68]. Currently, the effectiveness of the systemic markers of bone exchange 
to assess the risk of developing jaw necrosis in risk patients is being questioned, which 
requires more research before considering it as a valid risk evaluation tool. In the long term, 
prospective studies will be necessary to establish the efficacy of suppression period of these 
drugs (drug holidays) to reduce the risk of MRONJ in these patients.
The risk of MRONJ seems to be more associated to the duration of the treatment (≥3 years) 
than the dosage, since there has not been any information indicating that the monthly dosage 
of bisphosphonates is related, with a high or reduced risk of MRONJ when it is compared 
with the weekly dose program.
There a no solid recommendations based on clinical research for patients who take oral 
bisphosphonates. The Task Force strategies described above have remained essentially 
unchanged and are based on the clinical experience of the physicians (expert opinions) who 
participate in the care of these patients [24, 64, 68–70].
1.7.3.1. Patients who have taken oral bisphosphonates for less than 3 years and have no clinical risk 
factors, alterations and have the possibility of programmed surgery
Includes all the common procedures for oral and maxillofacial surgeons, periodontists and 
specialists.
If dental implants are placed, an informed consent must be presented in regards to possible 
implant failure and the possible osteonecrosis of the jaws, if the patient continues the oral 
Osteonecrosis of the Jaws. Prevalence, Risk Factors and Role of Microbiota and Inflammation...
http://dx.doi.org/10.5772/intechopen.69315
57
bisphosphonate treatment. It is also advisable to contact the doctor who initially prescribed 
the oral bisphosphonate to suggest monitoring of these patients and consider a possible alter-
native dose to the bisphosphonate, temporary suppression of the drug or an alternative to the 
medication.
1.7.3.2. Patients who have been administered oral bisphosphonates for less than 3 years associated 
with corticosteroids
If systemic conditions allow, the physician must be contacted to consider the interruption of 
the oral treatment for at least 3 months prior to the oral surgery. Reinstatement of bisphos-
phonate therapy should not take place until complete bone healing. These strategies are based 
on the opinion of experts with significant clinical experience and the hypothesis that concomi-
tant treatment with corticosteroids can increase the risk of developing MRONJ.
1.7.3.3. Patients who have been administered oral bisphosphonates for less than 3 years, with or 
without corticosteroids
If systemic conditions allow, the physician must be contacted to consider the interruption of 
the oral treatment for at least 3 months prior to the oral surgery and, similarly, bisphospho-
nate therapy should not be reinstated until complete bone healing.
1.7.4. CTXs (C-terminal telopeptide in serum)
This bone resorption biomarker has been used for years as a predictive factor for the devel-
opment of bisphosphonate-related osteonecrosis when deciding on the dental treatments 
for this type of patients [71]. In a study by Marx et al. (2007), they observed CTXs in fast-
ing samples to correlate the values and the period of use of oral bisphosphonates and to 
demonstrate if the increase in value could indicate a recovery in bone remodeling when 
suspending oral bisphosphonate treatment. Risk stratification was determined according to 
the obtained values, CTX under 100 pg/ml represented high risk, CTX between 100 pg/ml 
and 150 pg/ml represented moderate risk, while CTX above 150 pg/ml represented minimal 
risk. CTX values increased between 25.9 and 26.4 pg/ml for each drug holiday month from 
the bisphosphonates, which indicated a recovery of the bone remodeling and a directive in 
terms of when the oral surgical procedures could be developed at a lower risk. Additionally, 
it was observed that in terms of the drug suppression periods associated to CTX values, the 
latter rose above the threshold of 150 pg/ml, which coincides with spontaneous bone healing 
or a better response to complete healing after debridement. [68].
After years of research, a meta-analysis of nine controlled studies did not reveal significant 
differences in the mean values of CTXs among patients with MRONJ and controls (mean 
difference, −31.417; 95% confidence interval [CI], −91.560 to 28.726; P = 0.306). Additionally, a 
second meta-analysis of four studies did not show significant differences in the risk of osteo-
necrosis with CTX values below 150 pg/ml for patients with MRONJ in comparison with the 
controls (risk ratio, 1.892; 95% CI, 0.636–5.626; P = 0.251) [71].
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The term “Drug Holiday” has appeared recently as a preventative measure when certain risk 
odontological treatment must be performed or to improve healing after the appearance of 
osteonecrosis. There are several proposals but there is no clear consensus regarding bisphos-
phonate suppression periods (Table 3) [72].
Cancer patients benefit mainly from the therapeutic effects of bisphosphonates, such as 
the control of bone pain and the incidence of pathological fractures. An interruption of 
IV bisphosphonate therapy does not offer short-term benefits. However, if systemic condi-
tions allow, long-term suspension can be beneficial in the stabilization of the areas affected 
by MRONJ, which reduces the risk of necrosis in other locations and minimizes clinical 
symptoms [63, 64]. The oncologist’s role is very important to assess the risks and benefits of 
suppressing the treatment.
Regarding the interruption of oral bisphosphonate treatment in patients with MRONJ, a grad-
ual improvement of the disease has been proven [68]. The interruption of oral bisphospho-
nates for 6–12 months may favor healing, after the removal of a bone sequestration or after 
Guideline Bisphosphonate exposure history by route of administration
Oral Intravenous
ASBMR56 No specific guidelines given No guidelines given
AAOMS57 Less than 3 year duration: No guidelines given
No change to dosing
Less than 3 year duration and corticosteroids:
Cease: 3 months prior
Recommence: Osseous healing has occurred†
More than 3 year duration:
Cease: 3 months prior
Recommence: Osseous healing has occurred†
CCPG60 No specific guidelines given Cease: 3–6 months prior
Recommence: Full healing†
Mayo Clinic62 No guidelines given Cease: 1 month prior
Recommence: Full healing
MFA64 No guidelines given Low/intermediate risk of SRE:
Cease: 2–3 months prior
Recommence: 2–3 months after or full 
healing
†If systemic condition permits.
Table 3. Proposals in the bisphosphonates suppression rate [72].
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debridement. The decision to suppress the drug must be assessed by the physician and the 
patient, as long as the systemic conditions allow.
2. Bisphosphonates
2.1. Definition
Bisphosphonates are non-metabolizable pyrophosphate analogues that are deposited on 
the bones and prevent or improve bone complications of the patients with bone alterations. 
Different bisphosphonates differ depending on the alterations of the R-2 lateral chain struc-
ture. These R-2 lateral chains determine the efficiency and the cellular effects of the inhibi-
tion of bone resorption [73]. The bisphosphonates are internalized by osteoclasts, causing the 
interruption of bone resorption. They also have antigiogenic properties, since they reduce 
the circulating levels of vascular endothelial growth factor (VEGF) [74–78] and antineoplastic 
effects [79]. It has very little intestinal absorption and is excreted without being metabolized 
by the kidneys.
Until 2001, pamidronate (Aredia®) was the only drug approved in the USA for the treatment 
of bone metastasis. In 2002, the US Food and Drug Administration (FDA) [80] approved zole-
dronic acid (Zometa®) as a treatment for these patients. Currently, the annual transfusion 
of zoledronate (Reclast®) and the parenteral formulation of ibandronate (Bonviva®) adminis-
tered every 3 months has been approved by the FDA for the treatment of osteoporosis [81].
In 2003, using the articles by Marx [12] and Ruggiero et al. [25], they observed and reported 
on the cases of unhealed bone exposure in the maxillofacial region in patients treated with 
IV bisphosphonates and, after multiple further publications, in September 2004, Novartis the 
manufacturer of pamidronate (Aredia®) and zoledronic acid (Zometa), added the complica-
tions deriving from this treatment to the labeling of these drugs, with the purpose of warning 
the health care professionals of the possibility of developing osteonecrosis of the jaws [82].
2.2. Types of bisphosphonates
According to their chemical structure, these are divided into two groups.
Non-nitrogenous: These are very similar to natural pyrophosphate, such as etidronate or 
clodronate that contain CH3 and Cl groups instead of the R2 chain and a nitrogen-free ring, 
such as tiludronate. They are metabolized by macrophages in toxic analogues of adenosine 
triphosphate (ATP) [83].
Nitrogenous: They present higher power, such as zoledronate and pamidronate, with a pri-
mary atom of basic nitrogen with an alkyl chain. They have a power 10–100 times higher than 
non-nitrogenous. Mevalonate inhibits the cholesterol route through the farnesyl diphosphate 
synthase enzyme [83].
There is a great variety of bisphosphonates approved for clinical use in the USA (Table 4).
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2.2.1. IV bisphosphonates
It is estimated that over 2.8 million cancer patients from around the world have received treat-
ment with IV bisphosphonates since their introduction [84].
• Pamidronate (Aredia): a second-generation bisphosphonates that are administered every 
3–4 weeks at a dosage of 90 mg.
• Zoledronic acid (Zometa): a third-generation bisphosphonates, administered every 3–4 
weeks, at a dosage of 4 mg.
It is a heterocyclic imidazole and, to date, the most powerful bisphosphonate to be admin-
istered to humans. In a test on in-vitro bone resorption using mouse cranium, zoledronate 
was at least 100 times more powerful than pamidronate. Additionally, the in-vivo animal 
model of calcitriol-induced hypercalcemia in thyroparathyroidectomized rats was 850 times 
more active than pamidronate and over 4 times more powerful than clodronate. Of all the 
bisphosphonates under clinical evaluation, this is the one having a higher therapeutic rela-
tionship between the desired inhibition of bone resorption and the undesired inhibition of 
bone mineralization, furthermore, several toxicology studies proved that the compound is 
safe [85].
2.2.2. Oral bisphosphonates
Due to the proven clinical effectiveness, it is considered a first line therapy in the treatment of 
osteoporosis and they are the most prescribed antiresorptive agents.
• Alendronate (Fosamax): 70 mg once a week during the osteoporosis treatment or less, if it 
has been prescribed for the prevention of osteoporosis.
It has been proven to prevent approximately 50% of cases in the prevention of the bone loss in 
the spine or hips in menopausal women and the reduction of bone fractures [86, 87].
• Risedronate (Actonel): 35 mg once a week.
Generic name Commercial name Laboratory RP FDA-a
Pamidronate Aredia, IV Novartis 100 1991
Tiludronate Skelid, O Sanofi 10 1997
Alendronate Fosamax, O Merck 1000 1997
Etidronate Didronel, O Proctor & Gamble 1 1997
Risedronate Actonel, O Proctor & Gamble 5000 1998
Zoledrónic acid Zometa, IV Novartis 100,000 2001
Ibandronate Bonviva, O Roche 10,000 2005
Note: O: oral; IV: intravenous.
Table 4. Drugs approved in EEUU.
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In a prospective study with a large sample, risedronate produced a reduction of 30% in hip 
fractures [88, 89].
• Ibandronate (Boniva): is the latest drug to be approved by the FDA (March, 2005) for the 
treatment of osteoporosis and it is administered monthly.
• Etidronate (Didronel): prescribed for the Paget disease with a dose of 300–750 mg/day for 
6 months.
• Tiludronate (Skelid): prescribed for Paget disease with a dose of 400 mg/day for 3 months.
2.3. Metabolism
Bisphosphonates have an average life between 30 min and 2 h and are deposited in the loca-
tions with higher bone metabolism, and can remain at the bone level for approximately 10 
years. The highest concentration is located in urine and saliva, and the most frequent adverse 
effects are renal insufficiency and osteonecrosis [90–92]. The accumulative doses described by 
Maerevoet, is of 72 mg for 18 months [90, 93].
In the case of IV bisphosphonates, such as zolendronic acid, 40% is eliminated unaltered 
through urine after 24 h [94] and the remaining 60% are united at bone level due to the great 
affinity of hydroxyapatite. This phenomenon takes place in areas of bone remodeling, in 
which the periodical exchange produces unaltered kidney excretion after a long elimination 
phase [95]. The mean life of this second elimination phase may last months or years, depend-
ing on the duration of the bisphosphonate treatment [96].
Excretion of oral bisphosphonates has also been studied, for example, in a rat study, in which 
they administered risedronate orally, and determined that 80% of the drug was excreted 
through the kidneys 12 h after the administration of the drug. Additionally, the study con-
cluded that taking oral bisphosphonates with mineral water that contains high calcium and 
magnesium levels reduced the effect of the drug; therefore it is advisable to take it as soon as 
the patient wakes up and in a vertical position [97]. These authors previously described the 
effect of water in combination with taking alendronate [98].
2.4. Detection of bisphosphonates
The concentration of bisphosphonates in a specific bone location depends on the speed of 
bone remodeling and blood circulation [99]. It is important to know the concentration of accu-
mulated bisphosphonate in the bone to understand the long-term drug effect and its toxic-
ity. Today, numerous authors have been able to quantify these drugs in plasma and urine 
through mass spectrometry (MS), which requires a previous derivation process that allows 
to transform the bisphosphonates into more hydrophobic substances so they can be studied 
[100, 101].
The development of analysis methods for the detection of bisphosphonates in biological 
matrices, it is hard due to the chemical properties of these compounds. The detection of 
bisphosphonates in human biological matrices comes with certain difficulties and therefore a 
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broad range of analytic techniques have been described, such as gas chromatography [102], 
ion chromatography [103], capillary electrophoresis, ionization mass spectrometry by electro-
spray [104] and chromatography of fluids [105].
2.4.1. Mass spectrometry (MS)
A method for the extraction and detection of zoledronic acid in urine and blood plasma or 
even accumulated in the bone (in a mouse model) through the combination of chromatogra-
phy and mass spectrometry (MS) [100, 106].
In these studies, a higher accumulation of bisphosphonates in bone extracts of the mandible 
was detected, compared to other types of bones [106]. On the other hand, human urine and 
blood plasma detected a maximum concentration peak of the drug of 77 μM (5 h after the 
administration) and 1.5 μM (after 1 h), respectively [100]. This methodology achieves high 
sensitivity and specificity in the detection, however, it requires a pretty complex and ardu-
ous treatment of the sample requiring phases with chemical reactions to derive the complex. 
The complexity of the treatment of the sample can be a limiting factor when the number of 
samples to be analyzed is high, as in the case of the follow-up of the pharmacokinetics and the 
bioavailability of zoledronic acid since its administration. For this reason, it would be desir-
able to have a more efficient alternative method to detect this drug.
2.4.2. Nuclear magnetic resonance spectroscopy (NMR)
Nuclear magnetic resonance (NMR) spectroscopy is a useful technique in chemometrics that 
can be used for the characterization of simple or complex mixes of different sources and pro-
vide quantitative results. There is a great variety of “omics” applications for NMR, such as 
metabonomics, metabolomics, proteomics, transcriptomics, fluxomics, foodomics, lipidomics, fermenta-
nomics, isotopomics, etc. One of the areas with greater impact in biomedicine is metabolomics 
by NMR for the study of metabolites in different types of samples, such as biofluids (urine, 
saliva, blood plasma, blood serum, sweat, etc.), tissue extracts, cerebrospinal fluid, cells, etc. 
Metabolomics by NMR can be used to find biomarkers for the study, diagnosis and prog-
nosis of diseases. Similarly, it can help many traditional analysis at a clinical level, since the 
cost per sample is or can be competitive if large lots of samples are managed, in terms of the 
time for the analysis (measurement) and the generation of results (automated). There are a 
number of pathologies for which the study of biofluids or tissues by NMR has found useful 
biomarkers [107, 108]. A relevant case of application of NMR in this area is the quantification 
of lipoprotein in blood serum/plasma. NMR offers details on the relative abundance of differ-
ent subclasses of lipoproteins that are not accessible to traditional analysis methods [109, 110].
It is a quantitative technique that allows determination of the absolute concentration of 
diluted substances in general, including biofluids. It is based on the fact that the intensity 
of a signal in the NMR spectrum is proportionate to the concentration of the molecule (or 
metabolite) generating the said signal. As an approximate value, to assess the sensitivity of 
this technique, in a current spectrometer with a 11.7 T magnet, the minimum concentration 
required to detect a molecule in a monodimensional spectrum (1D) of 1H (proton spectrum, 
Osteonecrosis of the Jaws. Prevalence, Risk Factors and Role of Microbiota and Inflammation...
http://dx.doi.org/10.5772/intechopen.69315
63
as it is commonly known in our jargon) must amount to a minimum of 10 μm, for a measure-
ment period of 15 min.
For the case of urine samples, under these same measurement conditions, 50–60 metabolites 
can be identified and quantified in their proton spectrum (Figure 2).
Figure 2. Typical spectrum of 1H NMR of a human urine sample. The numbers indicate the following metabolites: 
1: creatinine, 2: citric acid, 3: glycine, 4: formic acid, 5: methanol, 6: guanidinoacetic acid, 7: acetic acid, 8: l-cysteine, 9: 
glycolic acid, 10: creatine, 11: Isocitric acid, 12: hippuric acid, 13: l-glutamine, 14: l-alanine, 15: l-Lysine, 16: gluconic acid, 
17: 2-hidoxiglutaric acid, 18: d-glucose, 19: indoxyl sulfate, 20: trimethyl-N-oxide, 21: ethanolamine, 22: l-lactic acid, 23: 
taurine, 24: l-threonine, 25: dimethylamine, 26: pyroglutamic acid, 27: trigonelline, 28: sucrose, 29: trimethylamine, 30: 
mannitol, 31: l-serine, 32: acetone, 33: l-cystine, 34: adipic acid, 35: l-histidine, 36: l-tyrosine, 37: imidazole, 38: mandelic 
acid, 39: dimethylglycine, 40: cis-aconitic acid, 41: urea, 42: 3-(3-Hydroxyphenyl)-3-hydroxypropanoic (HPHPA), 43: 
phenol, 45: isobutyric acid, 46: methylsuccinic acid, 47: 3-Aminoisobutíric acid, 48: l-fucose, 49: N-acetylaspartic acid, 50: 
N-acetylneuraminic, 51: acetoacetic acid, 52: Alpha-aminoadipic acid, 53: methylguanidine, 54: phenylacetylglutamine [111].
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When a series of NMR spectra need to be compared, such as urine, it is important to consider 
some details regarding post-processing of the spectra and the process to obtain their quanti-
tative values, in such a way that no errors are introduced in this phase and the quantitative 
results that are obtained are the most precise and repeatable as possible. Although with slight 
variations regarding some details, the general method for the treatment of spectral informa-
tion for the metabolomic studies by NMR is the one described below.
2.4.2.1. Preparation of a biofluid sample
A series of protocols have been established for the preparation of biofluid samples and their 
subsequent preservation until the NMR measuring [112, 113]. Similarly, there are experimen-
tal parameters to be used for the measurement of the NMR spectrum for each type of biofluid 
[112, 113]. These protocols standardize the measurements, thus allowing the comparison of 
the spectra obtained and the NMR spectrum (e.g. the Human Metabolome Database: www.
hmdb.ca) and/or with bibliographic results. These sample preparation protocols tend to be 
simple and do not require special laboratory equipment.
2.4.2.1.1. Generation of a signal intensity data matrix (integrals) on regions of interest (ROIs) of the 
NMR spectrum
The raw data provided by the spectrometer when measuring the 1H NMR spectrum is called 
free induction decay (FID). The data must be post-processed by applying a series of operations 
to generate a final spectrum with a scale of frequencies (expressed by standardized ppm units) 
and with the best quality possible [114]. Once the post-processing has been completed for each 
of the spectra to be studied, the following phase consists of comparing analogue regions of the 
spectrum with the target to find, if possible, a certain region that could serve as a biomarker, in 
other words, a region in which the signal’s intensity pattern is significantly different in the sam-
ples of the control group and the experiment group, while being similar within their own group.
Instead of manually selecting one or several regions for comparison, the usual and practical 
procedure is to perform a systematic analysis, dividing the entire spectrum automatically, 
from right to left, through a series of small segmental regions (e.g. with an established width) 
in which the area of the signal is integrated individually. Each of these regions is called buck-
ets or regions of interest (ROIs). This way, a complete spectrum is represented as a data vector 
formed by the integrals of the selected ROIs, with as many integral values as segments of the 
spectrum have been created.
Lastly, a table is created with the data, placing the vectors of each of the analyzed samples in 
different lines (Figure 3). There are software tools that automate these operations to generate 
the data table, as well as the phase before the post-processing.
2.4.2.2. Standardization of the data of the ROIs Matrix
Of the ROI matrix integral values, the negative values are initially purged since they only 
contain noise (a ROI must have at least an integral value or a signal area that equals zero).
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The ROIs data standardization process seeks to take all the analyzed samples to a “virtual” 
constant that eliminates all the differences in global concentration in the ROI integral samples, 
which could simply respond to the urine having a higher or lower concentration of H
2
O. When 
the dilution effect is eliminated, the differences between values of the same ROI in a pair of 
samples directly reflect variations in the relative concentration of the studied metabolite.
2.4.2.2.1. Standardization method of each ROI line at a standard addition
A first standardization method consists of standardizing the total addition of the ROIs. This 
method considers that the total addition of all the ROIs of the same spectrum has a constant 
value, and that this is the same for all the samples. This type of standardization by matrix lines 
consists of dividing each ROI value by the total addition of ROIs of its same line. As a result, 
the standardized ROIs of a sample add up to the unit.
Figure 3. Scheme for the construction of a NMR ROI data matrix from 53 NMR spectra. Above: 53 1H spectra in which 
we have selected certain ROIs for the integration of the signal. The vertical piling scale identifies each of the samples (# 
sample). The same color has been used to identify samples that should be, a priori, of the same type. Below: NMR ROIs 
data matrix obtained through the integration of each of the ROIs.
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2.4.2.2.2. Probabilistic quotient standardization method
This method consists of using the data of the ROIs of a certain sample of the study (a line of 
the matrix) and dividing the ROIs between those of another sample that is used as reference. 
This allows us to deduce the most probable multiplication factor so that the ROIs of the first 
sample are as close as possible to the reference sample. The most probable multiplication 
factor is calculated for each sample (for each line of the matrix). As a result of applying each 
factor on the ROIs of the relevant samples, their ROIs will be standardized as if the sample 
would have been prepared in the same concentration as the reference sample [115].
2.4.2.3. Statistical analysis of the NMR ROIs Matrix
The Matrix of standardized ROIs is analyzed by multivariate statistic methods to identify the 
ROIs that contain similar or different patterns of the integral in samples of the same or different 
group and their potential biomarkers. To do this, algorithms, such as the Principal Components 
Analysis (PCA), Discriminant Analysis (DA) and Orthogonal Projections to Latent Structures-
Discriminant Analysis (OPLS-DA) are used. These algorithms have been implemented in sev-
eral general statistical software packages, for example, R, SPSS or XLSLAT, among others.
In favorable cases, one or more ROIs with potential biomarkers related to the property under 
investigation are identified, for example, the effect of certain medical treatments, a type of 
diet, a disease, etc. Additional objectives can then be included in the study, such as the identi-
fication of what specific biomarkers (metabolites) were altered compared to the control group, 
to try to discover through which metabolic pathway they underwent this change. Some of 
the biomarkers that are identified as different from the control group may not correspond to 
any of those that are typically found in the relevant type of biofluid, but they may proceed 
from the metabolism of a drug or a special diet that has been prescribed. In this case, once its 
NMR signal has been identified, we could consider performing a longitudinal follow-up on 
its appearance in the biofluid since its administration.
2.5. Medication-related osteonecrosis of the jaw (MRONJ)
Currently, two types of drugs, aside from bisphosphonates, have been proven to cause necro-
sis of the jaws.
2.5.1. Antireabsorptives: denosumab
It is a RANKL monoclonal antibody that is currently still undergoing clinical trials for the 
treatment of osteoporosis, primary and metastatic bone cancer, giant cell tumor and rheuma-
toid arthritis [116, 117]. RANKL is necessary for the activation and function of mature osteo-
clasts [118, 119], which together with osteoprotegerin (OPG), maintains the balance of bone 
resorption in a healthy state. When an imbalance occurs in the RANKL/OPG ratio, resorption 
is favored in bone diseases [120, 121].
Denosumab has a high specificity due to human IgG2 that binds specifically to human RAN, 
and not other members of the TNF superfamily [116, 122, 123]. In clinical trials, this drug 
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causes rapid and prolonged decreases in bone exchange markers without any change in bone 
formation, which gives it antireabsorptives characteristics [124]. It has also shown better clini-
cal results compared to bisphosphonates in the treatment of osteoporosis and cancer with a 
higher increase in bone density and suppression of bone remodeling markers, with a proven 
efficacy even in patients who had been previously resistant to bisphosphonates [117, 125, 126].
These drugs also produce osteonecrosis of the jaws with a prevalence of 0.7–19% [127, 128], 
which is very similar to the osteonecrosis from bisphosphonate treatments [117]. Since the 
first case of maxillary osteonecrosis due to this drug published in 2010 [129], several stud-
ies have been published but only one of them describes histopathologic characteristics [130]. 
The fragments of necrotic bone showed empty osteocytic lacuna and absence of osteocytes, 
osteoblasts and osteoclasts. The authors suggest that these characteristics are very similar to 
bisphosphonate-related osteonecrosis [131]
2.5.2. Antiangiogenics
These drugs hinder the development of new blood vessels and block the cascade of angio-
genesis [132].
Bevacizumab: Monoclonal antibodies that stop the growth factor.
Suntinib and Sorafenib: Tyrosine kinase inhibitors.
3. Results of our experience
3.1. Regarding the risk factors
All the patients of this study visited the Master of Oral Medicine, Surgery and Implantology 
of the Faculty of Dentistry of the University of Santiago de Compostela. The patients were 
derived from the Unit of Oncology of the Complejo Hospitalario Universitario de Santiago de 
Compostela (CHUS) for a dental examination prior to treatment with intravenous bisphos-
phonates. The study was approved by the Clinical Research Ethics Committee of Galicia, in 
addition to the gaining informed consent from the patients.
Patients treated with zoledronic acid for a period of 7 years (2006–2013) and patients with a 
history of treatment of head and neck radiotherapy were excluded.
Local risk factors: Only those patients who underwent exodontics during bisphosphonate 
treatment had a statistically significant risk (P > 0.001), as well as a direct relationship accord-
ing to the periodontal status of the patient, since no patient with periodontal health developed 
MRONJ (P = 0.001). As previously described in the literature, research showed that the man-
dible is more affected than the upper maxilla and is also statistically significant (P < 0.001)
Systemic risk factors: There were no significant differences in terms of gender (P = 0.063). 
Age did not show significant differences but there were more cases of osteonecrosis in elderly 
patients, probably because these patients are more compromised at the systemic level; in fact, 
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86.6% of them were polymedicated. The type of cancer, arterial hypertension and treatment with 
chemotherapy or corticosteroids did not show statistically significant differences, although the 
literature describes them as obvious risk factors. We could only conclude that patients without 
diabetes did not develop MRONJ (P = 0.048). In our study we did not factor in their race, since 
100% of the patients were Caucasian and from a specific population. As described by Wessel 
et al. [29] in their study, 100% of our patients had bone metastases, which justified the use of 
intravenous bisphosphonates and, therefore, also implied an increased risk of complications.
Drug-related factors: Regarding potency, all patients were treated with the same bisphospho-
nate (zoledronic acid, 4 mg). The cumulative dose showed that patients with more than three 
years of treatment had a higher risk of developing MRONJ, which was statistically significant 
(P < 0.001) (Table 5).
3.2. Bacterial role in osteonecrosis of the jaws
We selected 28 patients (16 men and 12 women) with a mean age of 71.96 years, all of whom 
were treated in the Oncology Department of the Complejo Hospitalario Universitario 
de Santiago de Compostela (CHUS). They were referred to the Unit of Oral Surgery and 
Implantology of the Faculty of Medicine and Dentistry of Santiago de Compostela for a prior 
dental examination and for the follow-up of possible complications after treatment.
All patients treated with both oral and intravenous bisphosphonates and those undergoing 
head and neck radiotherapy within an 8-year period were included (2006–2014). The diag-
nostic criteria followed were those determined by the AAOMS [15] for patients treated with 
bisphosphonates, while in the case of those undergoing radiotherapy, we included those who 
had bone exposure for more than 8 weeks.
Samples of exudates from bone exposure were sent to the Department of Microbiology to 
be processed under Gram staining and seeded in liquid medium (thioglycolate broth) and 
in solids (agar-blood and agar-chocolate for the growth of aerobic bacteria, Sabouraud agar 
for yeast growth and Schaedler agar for anaerobic growth). The seeded plates were incu-
bated for 48 h at 37°C in a CO
2
 atmosphere and 72 h in anaerobic chambers. Identification of 
microorganisms was done using the Vitek 2 system (Bio-Merieux, Marcy l’Etoile, France) and 
Microscam (Siemens, Erlangen, Germany) in the case of aerobes; and API-ANA (Biomeriex) 
in the case of anaerobes. Antimicrobial susceptibility testing was performed by the e-test 
method (AB biodisk) and the Clinical Laboratory Standards Institute (CLSI) interpretation 
criteria were followed.
Biopsies of bone sequestration were sent to the Pathological Anatomy Service where they were 
fixed in 10% buffered formaldehyde and embedded in paraffin following standard processing. 
For evaluation, they were stained with hematoxylin/eosin, PAS and methenamine silver to 
visualize the colonies of Actinomyces. Their presence was evaluated semi-quantitatively and 
divided into scarce, moderately abundant or very abundant. In addition, the presence of acute 
inflammation (when polymorphonuclear neutrophil cells were observed), which was also 
quantified in three degrees: mild, moderate and intense, and the presence of chronic inflam-
mation (indicated by the presence of lymphocytes and plasma cells).
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Characteristics Total patients with ONJ (%) Total patients without ONJ (%) P
Gender 0.063
Men 14 (7.2) 125 (64.4)
Women 11 (5.7) 44 (22.7)
Systemic Risk Factor 0.214
Cancer 12 (6.2) 95 (49)
 Prostate 9 (4.6) 34 (17.5)
 Breast 4 (2) 11 (5.7)
 Myeloma 0 (0) 18 (9.3)
 Lung 0 (0) 2 (1)
 Bladder 0 (0) 5 (2.6)
 Colon 0 (0) 3 (1.5)
 Kidney 18 (9.3) 176 (90.7)
Diabetes 168 (86.6) 26 (13.4) 0.048
Polymedicated. 94 (48.5) 100 (51.5) 0.139
HTA 42 (21.6) 152 (78.4) 0.704
Cortisone 65 (33.5) 129 (66.5) 0.234
QTP 11 (5.7) 54 (27.8) 0.462
Local Risk Factor
Extraction Before 8 (4.1) 86 (44.3) 0.078
Extraction during 5 (2.6) 1 (0.5) <0.001
Extraction after 4 (2) 7 (3.6) 0.017
Prosthesis 5 (2.6) 33 (17) 0.936
periodontal state 19 (9.8) 70 (36) 0.001
Toxic factors 0.998
Tobacco 2 (1) 13 (6.7)
Alcohol 3 (1.5) 19 (9.8)
Location
Unifocal mandible 13 (6.7) – <0.001
Unifocal maxilla 5 (2.6) –
Multifocal mandible 3 (1.5) –
Maxilla and mandible 4 (2) –
Table 5. Risk factors in the occurrence of ONJ.
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The collected data were analyzed with the SPSS statistical system, version 20.0 for Windows. 
The discontinuous quantitative or discreet variables were analyzed through descriptive sta-
tistics, expressing the results in mean, deviation and standard. The frequency tables and per-
centages were used for qualitative variables. For the study of the association of variables we 
employed the chi-squared test, the T-Student test or the ANOVA factor test, depending on 
the application conditions. Values in which P ≤ 0.05 were considered statistically significant.
3.2.1. Clinical results
Of the 28 patients, 16 were men (57.1%) and 12 women (48.8%) with a mean age of 71.96 years 
(SD 8.94). According to the risk factors analyzed, 8 patients (28.5%) were diabetic, 15 (53.6%) 
were undergoing chemotherapy, 4 were smokers (14.3%), 14 was hypertensive (50%) and 9 
(32.1%) were taking corticosteroids. The reason for treatment with bisphosphonates was oral 
cancer (14.3%), breast cancer (25%), prostate cancer (39.2%), multiple myeloma (10.7%) and 
osteoporosis (10.7%).
The most affected region of the mouth was the mandible (67.8%) followed by the upper jaw 
(21.4%) or both (10.7%).
The degree of affectation was variable depending on the type of treatment. Patients on intra-
venous bisphosphonates had all stages of ONJ, whereas patients undergoing the oral treat-
ment had only stage II ONJ and patients treated with radiotherapy showed both stage II (5%) 
and stage III (75%).
3.2.2. Histological results
A total of 24 of 28 patients underwent a histological study with a biopsy of a bone sequestra-
tion lesion. Of these, in 21 patients (87.5%) we proved the presence of Actinomyces within the 
3 degrees of osteonecrosis of the jaws. The amount of Actinomyces present was quantified 
semi-quantitatively by the pathologist. The pathogen count was very abundant in degrees I 
and II, while in degree III the patients had lower amounts of Actinomyces (Figure 4).
The degree of acute and/or chronic inflammation was also evaluated. In 54.2% of the patients, 
the presence of Actinomyces was not accompanied by any sign of inflammation; while in 
the rest of the patients, it was observed that as age increased, the intensity of the inflamma-
tion also increased; therefore a lower mean age accounted for the absence of inflammation 
(65.31; SD: 7.91) contrasting with abundant inflammation (81.00; SD: 2.83). Such differences 
were statistically significant (F = 5.270, P = 0.005). There was acute inflammation in 37.5% of 
the patients being quantified as mild inflammation (two patients), moderate (five patients) 
and severe (two patients); the latter two were present in patients with grade II osteonecrosis, 
exclusively. There were only two chronic inflammation cases, one patient with grade II and 
another with grade III ONJ.
The relationship between the amount of Actinomyces present in the histological sections and 
the degree of inflammation observed in bone sequestration was evaluated. Despite not hav-
ing statistically significant data, it was observed that the high amount of Actinomyces could 
trigger either null or an abundant inflammatory response (Table 6).
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3.2.3. Microbiological results
Regarding the isolation of bacteria obtained through suppuration of the necrosed area, all the 
bacteria described by the microbiologist were recorded, which were later classified accord-
ing to their aerobic or anaerobic metabolism. Aerobic bacteria were mostly found (85%) in 
patients with grade I and II of ONJ, being statistically significant (P = 0.002). However, anaero-
bic bacteria were present in 56% of the patients in the three stages of ONJ. Although all the 
cases of grade III presented anaerobic bacteria, this data were not statistically significant.
Figure 4. Histological image of bone sequestration. Histopathologic examination revealed different combinations of 
Actinomyces and the inflammatory response. Some cases showed abundant colonies of Actinomyces, but lacked any 
inflammatory infiltration (A); while in other examples this microorganism was identified along with a dense PMN 
infiltrate (B). PMNs were also seen in some cases, in the absence of Actinomyces (C). Last of all, in some patients, the 
only change consisted of fibrosis and the scarce inflammatory response was composed mainly of lymphocytes (D).
Inflammation
Actinomyces Null Mild Moderate Abundant Chronic
Null 0 0 1 0 0
Scarce 1 0 1 0 1
Moderate 8 1 1 0 1
Abundant 4 1 2 2 0
Table 6. Relationship of the amount of Actinomyces and the inflammatory response.
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There was practically no significance in the families of bacterial species specific to the differ-
ent degrees of osteonecrosis, except Streptococcus sp. which was very abundant in grade II of 
ONJ. Only three bacteria showed statistically significant differences in relation to the ONJ 
stages (Table 7, Figure 5).
Antibiograms were also performed for each of the species found, in order to guide the anti-
biotic pattern of these patients. We studied the six most common antibiotics, as well as the 
specific ones for the pathology described in the literature, we observed a variable bacterial 
behavior among the patients with osteonecrosis of the jaws.
Penicillin G did not show complete sensitivity in any patient against all the bacteria isolated 
in the cultures, in addition, there was much variability among patients regarding the response 
to this antibiotic (Figure 6).
The combination of amoxicillin and clavulanic acid showed good sensitivity in most patients 
(82.6%) although this was not statistically significant (Figure 7).
Clindamycin was effective in 40% of patients and resistant in 14.5%, while 28% of the patients 
showed variability in the response to this antibiotic. Azithromycin was effective in a few 
patients (38%) and the response was highly variable, without showing complete sensitivity to 
isolated bacteria (Figure 8).
Levofloxacin was effective in 42.8% of the patients, which showed good sensitivity in most 
cases (88.8%). Last of all, gentamicin, another antibiotic which is less frequent in our daily 
practice, showed good sensitivity although it was effective in few patients (38%).
Grade I Grade II Grade III P value
Staphylococcus sp. 0 1 1 0.372
Capnocytophaga sp. 2 l 0 0.008
Morganella morganii 0 1 0 0.817
Enterobacter cloacae 0 1 2 0.037
Streptococcus sp. 3 12 1 0.112
Eikenella corrodens 0 3 1 0.664
Neisseria sp. 3 3 0 0.004
Proteus sp. 0 1 0 0.074
Actinomyces sp. 2 3 0 0.003
Veionella parvula 0 0 2 0.817
Peptostreptococcus sp. 0 3 0 0.515
Fusobacterium sp. 0 1 1 0.372
Prevotella sp. 0 4 1 0.648
Bacteroides sp. 0 2 0 0.655
Table 7. Relationship between the isolated type of bacteria and the degree of ONJ.
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Figure 5. Relationship between the isolated type of bacteria and the degree of ONJ.
Figure 6. Antibiogram of Penicillin G.
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Figure 7. Antibiogram of the association of amoxicillin with clavulanic acid.
Figure 8. Clindamycin antibiogram.
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